Buena ocación para Zeltia

Buena ocación para que Zeltia de a conocer sus medicamentos contra el cáncer

MARKET SENTIMENT

-The broad market is expected to open higher, on the back of gains in Asia overnight with focus later in the session on a slew of US data and Wall Street's response after yesterday's holiday.

-On specific stocks, Repsol could get a boost by a report that Sacyr does not plan to sell its around 20 percent stake, while Zeltia will also be in the limelight ahead of the upcoming American Society of Clinical Oncology conference, where an update on the commercialisation of its flagship anti- cancer drug Yondelis, as well as other compounds, is expected.

http://www.forbes.com/afxnewslimited/feeds/afx/2008/05/27/afx5048332.html